The trademark application MEVALGINE was filed by AXIENCE SAS, a corporation established under the laws of the French Republic (the "Applicant"). The application was published for oppositions on August 27, 2020, and it was registered by office on December 7, 2020 without any oppositions.
The application was filed in French (English was selected as the second language).